Cargando…

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes

AIMS/HYPOTHESIS: The central nervous system (CNS) is a major player in the regulation of food intake. The gut hormone glucagon-like peptide-1 (GLP-1) has been proposed to have an important role in this regulation by relaying information about nutritional status to the CNS. We hypothesised that endog...

Descripción completa

Detalles Bibliográficos
Autores principales: ten Kulve, Jennifer S., Veltman, Dick J., van Bloemendaal, Liselotte, Barkhof, Frederik, Deacon, Carolyn F., Holst, Jens J., Konrad, Robert J., Sloan, John H., Drent, Madeleine L., Diamant, Michaela, IJzerman, Richard G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630252/
https://www.ncbi.nlm.nih.gov/pubmed/26385462
http://dx.doi.org/10.1007/s00125-015-3754-x
_version_ 1782398669619724288
author ten Kulve, Jennifer S.
Veltman, Dick J.
van Bloemendaal, Liselotte
Barkhof, Frederik
Deacon, Carolyn F.
Holst, Jens J.
Konrad, Robert J.
Sloan, John H.
Drent, Madeleine L.
Diamant, Michaela
IJzerman, Richard G.
author_facet ten Kulve, Jennifer S.
Veltman, Dick J.
van Bloemendaal, Liselotte
Barkhof, Frederik
Deacon, Carolyn F.
Holst, Jens J.
Konrad, Robert J.
Sloan, John H.
Drent, Madeleine L.
Diamant, Michaela
IJzerman, Richard G.
author_sort ten Kulve, Jennifer S.
collection PubMed
description AIMS/HYPOTHESIS: The central nervous system (CNS) is a major player in the regulation of food intake. The gut hormone glucagon-like peptide-1 (GLP-1) has been proposed to have an important role in this regulation by relaying information about nutritional status to the CNS. We hypothesised that endogenous GLP-1 has effects on CNS reward and satiety circuits. METHODS: This was a randomised, crossover, placebo-controlled intervention study, performed in a university medical centre in the Netherlands. We included patients with type 2 diabetes and healthy lean control subjects. Individuals were eligible if they were 40–65 years. Inclusion criteria for the healthy lean individuals included a BMI <25 kg/m(2) and normoglycaemia. Inclusion criteria for the patients with type 2 diabetes included BMI >26 kg/m(2), HbA(1c) levels between 42 and 69 mmol/mol (6.0–8.5%) and treatment for diabetes with only oral glucose-lowering agents. We assessed CNS activation, defined as blood oxygen level dependent (BOLD) signal, in response to food pictures in obese patients with type 2 diabetes (n = 20) and healthy lean individuals (n = 20) using functional magnetic resonance imaging (fMRI). fMRI was performed in the fasted state and after meal intake on two occasions, once during infusion of the GLP-1 receptor antagonist exendin 9-39, which was administered to block actions of endogenous GLP-1, and on the other occasion during saline (placebo) infusion. Participants were blinded for the type of infusion. The order of infusion was determined by block randomisation. The primary outcome was the difference in BOLD signal, i.e. in CNS activation, in predefined regions in the CNS in response to viewing food pictures. RESULTS: All patients were included in the analyses. Patients with type 2 diabetes showed increased CNS activation in CNS areas involved in the regulation of feeding (insula, amygdala and orbitofrontal cortex) in response to food pictures compared with lean individuals (p ≤ 0.04). Meal intake reduced activation in the insula in response to food pictures in both groups (p ≤ 0.05), but this was more pronounced in patients with type 2 diabetes. Blocking actions of endogenous GLP-1 significantly prevented meal-induced reductions in bilateral insula activation in response to food pictures in patients with type 2 diabetes (p ≤ 0.03). CONCLUSIONS/INTERPRETATION: Our findings support the hypothesis that endogenous GLP-1 is involved in postprandial satiating effects in the CNS of obese patients with type 2 diabetes. Trial registration: ClinicalTrials.gov NCT 01363609 Funding The study was funded in part by a grant from Novo Nordisk.
format Online
Article
Text
id pubmed-4630252
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-46302522015-11-06 Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes ten Kulve, Jennifer S. Veltman, Dick J. van Bloemendaal, Liselotte Barkhof, Frederik Deacon, Carolyn F. Holst, Jens J. Konrad, Robert J. Sloan, John H. Drent, Madeleine L. Diamant, Michaela IJzerman, Richard G. Diabetologia Article AIMS/HYPOTHESIS: The central nervous system (CNS) is a major player in the regulation of food intake. The gut hormone glucagon-like peptide-1 (GLP-1) has been proposed to have an important role in this regulation by relaying information about nutritional status to the CNS. We hypothesised that endogenous GLP-1 has effects on CNS reward and satiety circuits. METHODS: This was a randomised, crossover, placebo-controlled intervention study, performed in a university medical centre in the Netherlands. We included patients with type 2 diabetes and healthy lean control subjects. Individuals were eligible if they were 40–65 years. Inclusion criteria for the healthy lean individuals included a BMI <25 kg/m(2) and normoglycaemia. Inclusion criteria for the patients with type 2 diabetes included BMI >26 kg/m(2), HbA(1c) levels between 42 and 69 mmol/mol (6.0–8.5%) and treatment for diabetes with only oral glucose-lowering agents. We assessed CNS activation, defined as blood oxygen level dependent (BOLD) signal, in response to food pictures in obese patients with type 2 diabetes (n = 20) and healthy lean individuals (n = 20) using functional magnetic resonance imaging (fMRI). fMRI was performed in the fasted state and after meal intake on two occasions, once during infusion of the GLP-1 receptor antagonist exendin 9-39, which was administered to block actions of endogenous GLP-1, and on the other occasion during saline (placebo) infusion. Participants were blinded for the type of infusion. The order of infusion was determined by block randomisation. The primary outcome was the difference in BOLD signal, i.e. in CNS activation, in predefined regions in the CNS in response to viewing food pictures. RESULTS: All patients were included in the analyses. Patients with type 2 diabetes showed increased CNS activation in CNS areas involved in the regulation of feeding (insula, amygdala and orbitofrontal cortex) in response to food pictures compared with lean individuals (p ≤ 0.04). Meal intake reduced activation in the insula in response to food pictures in both groups (p ≤ 0.05), but this was more pronounced in patients with type 2 diabetes. Blocking actions of endogenous GLP-1 significantly prevented meal-induced reductions in bilateral insula activation in response to food pictures in patients with type 2 diabetes (p ≤ 0.03). CONCLUSIONS/INTERPRETATION: Our findings support the hypothesis that endogenous GLP-1 is involved in postprandial satiating effects in the CNS of obese patients with type 2 diabetes. Trial registration: ClinicalTrials.gov NCT 01363609 Funding The study was funded in part by a grant from Novo Nordisk. Springer Berlin Heidelberg 2015-09-18 2015 /pmc/articles/PMC4630252/ /pubmed/26385462 http://dx.doi.org/10.1007/s00125-015-3754-x Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
ten Kulve, Jennifer S.
Veltman, Dick J.
van Bloemendaal, Liselotte
Barkhof, Frederik
Deacon, Carolyn F.
Holst, Jens J.
Konrad, Robert J.
Sloan, John H.
Drent, Madeleine L.
Diamant, Michaela
IJzerman, Richard G.
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
title Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
title_full Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
title_fullStr Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
title_full_unstemmed Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
title_short Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
title_sort endogenous glp-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630252/
https://www.ncbi.nlm.nih.gov/pubmed/26385462
http://dx.doi.org/10.1007/s00125-015-3754-x
work_keys_str_mv AT tenkulvejennifers endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT veltmandickj endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT vanbloemendaalliselotte endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT barkhoffrederik endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT deaconcarolynf endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT holstjensj endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT konradrobertj endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT sloanjohnh endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT drentmadeleinel endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT diamantmichaela endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes
AT ijzermanrichardg endogenousglp1mediatespostprandialreductionsinactivationincentralrewardandsatietyareasinpatientswithtype2diabetes